Arcadia Biosciences Valuation
| RKDA Stock | USD 2.79 0.03 1.09% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Arcadia Biosciences shows a prevailing Real Value of $2.76 per share. The current price of the firm is $2.79. Our model approximates the value of Arcadia Biosciences from analyzing the firm fundamentals such as return on equity of -0.53, and Profit Margin of (1.12) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Arcadia Biosciences' valuation include:
Price Book 0.3702 | Enterprise Value -2.4 M | Enterprise Value Ebitda 0.6173 | Price Sales 0.7347 | Forward PE 34.8432 |
Fairly Valued
Today
Please note that Arcadia Biosciences' price fluctuation is dangerous at this time. Calculation of the real value of Arcadia Biosciences is based on 3 months time horizon. Increasing Arcadia Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Arcadia Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arcadia Stock. However, Arcadia Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.79 | Real 2.76 | Target 15.0 | Hype 2.79 | Naive 3.05 |
The real value of Arcadia Stock, also known as its intrinsic value, is the underlying worth of Arcadia Biosciences Company, which is reflected in its stock price. It is based on Arcadia Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Arcadia Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Arcadia Biosciences helps investors to forecast how Arcadia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcadia Biosciences more accurately as focusing exclusively on Arcadia Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Arcadia Biosciences' intrinsic value based on its ongoing forecasts of Arcadia Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Arcadia Biosciences' closest peers. If more than one evaluation category is relevant for Arcadia Biosciences we suggest using both methods to arrive at a better estimate.
Arcadia Biosciences Cash |
|
Arcadia Valuation Trend
Comparing Arcadia Biosciences' enterprise value against its market capitalization is a good way to estimate the value of Arcadia Biosciences uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Arcadia Biosciences Total Value Analysis
Arcadia Biosciences is at this time forecasted to have valuation of (2.42 M) with market capitalization of 3.81 M, debt of 1.01 M, and cash on hands of 21.23 M. The negative valuation of Arcadia Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Arcadia Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(2.42 M) | 3.81 M | 1.01 M | 21.23 M |
Arcadia Biosciences Investor Information
The company has price-to-book ratio of 0.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Arcadia Biosciences recorded a loss per share of 6.77. The entity last dividend was issued on the 24th of January 2018. The firm had 1:40 split on the 1st of March 2023. Based on the key indicators related to Arcadia Biosciences' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Arcadia Biosciences is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Arcadia Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcadia Biosciences has an asset utilization ratio of 27.05 percent. This suggests that the Company is making $0.27 for each dollar of assets. An increasing asset utilization means that Arcadia Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Arcadia Biosciences Ownership Allocation
Almost 92.71 percent of Arcadia Biosciences outstanding shares are held by general public with 2.7 (percent) owned by insiders and only 4.59 % by other corporate entities.Arcadia Biosciences Profitability Analysis
The company reported the previous year's revenue of 5.33 M. Net Loss for the year was (13.99 M) with loss before overhead, payroll, taxes, and interest of (2.22 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Arcadia Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Arcadia Biosciences and how it compares across the competition.
About Arcadia Biosciences Valuation
The stock valuation mechanism determines Arcadia Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Arcadia Biosciences. We calculate exposure to Arcadia Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcadia Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2 M | 2.1 M | |
| Pretax Profit Margin | (2.47) | (2.59) | |
| Operating Profit Margin | (2.62) | (2.75) | |
| Net Loss | (2.62) | (2.75) | |
| Gross Profit Margin | 0.38 | 0.57 |
Arcadia Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.2 M | |
| Quarterly Earnings Growth Y O Y | 0.285 | |
| Forward Price Earnings | 34.8432 |
Arcadia Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Arcadia Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Arcadia we look at many different elements of the entity such as Arcadia's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Arcadia Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Arcadia Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Arcadia Biosciences' worth.Complementary Tools for Arcadia Stock analysis
When running Arcadia Biosciences' price analysis, check to measure Arcadia Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcadia Biosciences is operating at the current time. Most of Arcadia Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcadia Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcadia Biosciences' price. Additionally, you may evaluate how the addition of Arcadia Biosciences to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |